Europe
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication. Why they are shutting it down? Know all about it here.
“Hopefully the approval process will go very quickly, and we think we have a winner here,” Trump told White House reporters on Wednesday.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The U.S. Food and Drug Administration (FDA) approved Xywav, the first new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.
Only days after announcing a COVID-19 vaccine production deal with the UK government, New York-based Pfizer and Germany-based BioNTech signed an even bigger deal with the U.S. government.
In an ongoing online hearing before the House Committee on Energy and Commerce’s Oversight and Investigation subcommittee, executives from across the pharmaceutical industry outlined the steps their companies are taking to combat COVID-19 and restore the world to a sense of normalcy.
Oxford University, which by many standards is ahead of everyone in the vaccine development world, is suggesting end of the year is possible, but being very cautious about it.
PRESS RELEASES